drugset / Trial / NCT03356782
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NaSingle-groupOpen-labelTreatment
Summary
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines CAR T cells and IgT cells to treat sarcoma.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sarcoma-specific CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Sarcoma-specific CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |